1. In comparison to the 2002 severe acute respiratory syndrome (SARS) outbreak and the 2012 Middle Eastern respiratory syndrome (MERS) outbreak, COVID-19 has spread
A. To fewer countries but involving more people
B. To more countries but involving fewer people
C. To fewer countries and involving fewer people
D. To more countries and involving more people
2. The transition from mild/moderate symptoms to more severe stages of COVID-19 is marked by the onset of
A. Multi-organ failure
B. Acute respiratory distress syndrome
C. Loss of or reductions in smell or taste
D. Refractory, nonproductive cough
3. Which of the following are defined as typical symptoms of COVID-19?
A. Fever, cough, and shortness of breath
B. Shortness of breath, dizziness, and myalgia
C. Myalgia, cough, and sore throat
D. Sore throat, malaise, and fever
4. Terminal events in critically ill patients with COVID-19 include which of the following?
A. Septic shock and metabolic alkalosis
B. Metabolic alkalosis and coagulation dysfunction
C. Coagulation dysfunction and multi-organ failure
D. All of the above
5. Actions taken in the United States during the containment phase of the public health response to SARS-CoV-2 included which of the following?
A. Social distancing
B. Contact tracing
C. Stay-at-home orders
D. Universal facemasks for health care workers
6. Which of the following statements best describes past efforts to develop vaccines for coronaviruses?
A. Vaccines against SARS and MERS provided long-lasting immunity.
B. A vaccine against SARS provided long-lasting immunity.
C. A vaccine against MERS provided long-lasting immunity.
D. No vaccines against SARS and MERS provided long-lasting immunity.
7. Based on the genetic make-up of SARS-CoV-2, which of the following drug classes is most likely to prove effective?
A. Neuraminidase inhibitors
B. Nucleoside analogues
C. Protease inhibitors
D. Angiotensin converting enzyme inhibitors
8. Against SARS-CoV-2, remdesivir has demonstrated which of the following actions?
A. Strong in vitro activity
B. Weak activity in animal models
C. Protective effects in clinical trials
D. Clinical effectiveness but use limited by viral resistance
9. Antiviral activity of hydroxychloroquine is based on which of the following effects?
A. Inhibits release of virions from the host cell
B. Interrupts replication of viral RNA
C. Interrupts transcription of viral RNA
D. Interferes with viral entry into the host cell
10. An 83-year-old woman has COVID-19 of 15 days' duration. Her clinical course is significant for rapid decline after day 12, with low oxygen levels and fever of 38.9°C. Therapy with which of the following agents would be appropriate based on recommendations of the Surviving Sepsis Campaign?
A. Hydroxychloroquine
B. Intravenous immunoglobulin
C. Acetaminophen
D. Tocilizumab
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
